We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-8.6%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$215M
Cap. Flow
-$75.2M
Cap. Flow %
-8.35%
Top 10 Hldgs %
51.77%
Holding
78
New
10
Increased
19
Reduced
15
Closed
15

Top Buys

1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$17.3M
2
HRTX icon
Heron Therapeutics
HRTX
+$16.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
4
VCYT icon
Veracyte
VCYT
+$13.4M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.22M

Top Sells

1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$43.2M
2
ANGO icon
AngioDynamics
ANGO
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.9M
4
DVAX
Dynavax Technologies
DVAX
+$14.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13M

Sector Composition

1 Healthcare 88.9%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$96.4M 10.71%
5,959,819
+456,637
+8% +$8.28M
PGNX
2
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$77.3M 8.59%
8,951,169
– –
TVTX icon
3
Travere Therapeutics
TVTX
$5.27B
$61.9M 6.87%
3,269,271
-200,000
-6% -$4.09M
HRTX icon
4
Heron Therapeutics
HRTX
$89.1M
$51.1M 5.67%
3,899,587
+1,049,587
+37% +$16.5M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$45.7M 5.07%
4,394,464
– –
ATRS
6
DELISTED
Antares Pharma, Inc.
ATRS
$30.2M 3.36%
12,971,093
-1,914,300
-13% -$3.65M
PETX
7
DELISTED
Aratana Therapeutics, Inc.
PETX
$26.5M 2.95%
3,695,442
+609,463
+20% +$4.93M
LJPC
8
DELISTED
La Jolla Pharmaceutical Company
LJPC
$26.5M 2.94%
1,510,316
+63,263
+4% +$1.21M
ENDP
9
DELISTED
Endo International plc
ENDP
$25.7M 2.85%
1,560,038
+105,500
+7% +$1.86M
SCTL
10
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$25M 2.77%
3,456,596
+724,750
+27% +$4.96M
ANGO icon
11
AngioDynamics
ANGO
$558M
$24.8M 2.76%
1,471,152
-1,419,527
-49% -$23.7M
TEVA icon
12
Teva Pharmaceuticals
TEVA
$37.3B
$23.5M 2.61%
647,500
+347,500
+116% +$13.9M
ARLZ
13
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$21.1M 2.35%
4,791,590
+384,600
+9% +$1.83M
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.23B
$18.3M 2.04%
2,638,259
– –
GNMX
15
DELISTED
Aevi Genomic Medicine Inc
GNMX
$17.5M 1.94%
3,370,306
– –
NVLN
16
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$16.4M 1.82%
+1,948,554
New +$17.3M
MDCO
17
DELISTED
Medicines Co
MDCO
$14.8M 1.64%
436,400
+180,800
+71% +$6.41M
VCYT icon
18
Veracyte
VCYT
$4.72B
$13.8M 1.54%
+1,788,266
New +$13.4M
DSCI
19
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$13.3M 1.48%
2,562,104
– –
HZNP
20
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.9M 1.44%
800,000
-250,000
-24% -$4.53M
TLGT
21
DELISTED
Teligent, Inc
TLGT
$12.8M 1.42%
193,171
-27,019
-12% -$1.9M
ACOR
22
DELISTED
Acorda Therapeutics
ACOR
$12.1M 1.34%
5,368
+329
+7% +$782K
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$12.1M 1.34%
786,134
– –
RXDX
24
DELISTED
Ignyta, Inc.
RXDX
$12M 1.33%
2,256,546
– –
DRRX
25
DELISTED
DURECT Corp
DRRX
$11.4M 1.27%
850,623
+211,102
+33% +$2.7M
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Broadfin Capital held 78 positions worth $901M, down 19% from $1.12B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $75.2M in Q4 2016, closing 15 positions and reducing 15 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in Novelion Therapeutics Inc. Common Shares worth $16.4M.

  • Broadfin Capital's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 1,948,554 shares worth $16.4M.
  • Broadfin Capital added most to Heron Therapeutics in Q4 2016, an estimated $16.5M increase.
  • Broadfin Capital's biggest Q4 2016 reduction was Novadaq Technologies Inc., cutting an estimated $43.2M.
  • Broadfin Capital fully exited IVERIC bio, Inc. Common Stock in Q4 2016, selling an estimated $18.9M.
  • Broadfin Capital's ten largest holdings make up 52% of its $901M portfolio in Q4 2016.
  • Broadfin Capital opened 10 new positions and closed 15 in Q4 2016.
  • Broadfin Capital's portfolio value fell 19% quarter-over-quarter to $901M.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.